Study identifier:D2610C00002
ClinicalTrials.gov identifier:NCT01213160
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies
cancer
Phase 1
No
AZD4547
All
40
Interventional
25 Years - 150 Years
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jun 2016 by AstraZeneca
AstraZeneca
-
The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies.
Location
Location
Nagoya-shi, Japan
Location
Sapporo-shi, Japan
Location
Chuo-ku, Japan
Arms | Assigned Interventions |
---|---|
Experimental: AZD4547 | Drug: AZD4547 film coated tablet, PO, twice daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.